RAPILYSIN

This brand name is authorized in Australia, Austria, Croatia, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Italy, Lithuania, New Zealand, Poland, Turkey.

Active ingredients

The drug RAPILYSIN contains one active pharmaceutical ingredient (API):

1	Reteplase UNII DQA630RIE9 - RETEPLASE
	Reteplase is a recombinant plasminogen activator that catalyzes the cleavage of endogenous plasminogen to generate plasmin. This plasminogenolysis occurs preferentially in the presence of fibrin. Plasmin in turn degrades fibrin, which is the main component of the matrix of thrombi, thereby exerting its thrombolytic action.
	Read more about Reteplase

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
RAPILYSIN Powder and solvent for solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B01AD07	Reteplase	B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AD Enzymes
Discover more medicines within B01AD07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	8253J
EE	Ravimiamet	1112241
FI	Lääkealan turvallisuus- ja kehittämiskeskus	159772
FR	Base de données publique des médicaments	63335058
HK	Department of Health Drug Office	43305
IT	Agenzia del Farmaco	033131018
LT	Valstybinė vaistų kontrolės tarnyba	1030616
NZ	Medicines and Medical Devices Safety Authority	7667
PL	Rejestru Produktów Leczniczych	100125566
TR	İlaç ve Tıbbi Cihaz Kurumu	8699638274796